[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:axl-gene":3},{"name":4,"total":5,"recruiting":5,"trials":6},"AXL Gene",3,[7,15,22],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05168618","Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer",[11],"Phase 2","RECRUITING","2026-08-26T02:17:17.791881Z","2026-07-05T05:32:16.800551Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT07619313","AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer",[19],"Phase 1","2026-08-26T02:16:54.044282Z","2026-06-04T01:30:07.902796Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT01639508","Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity",[11],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:29.394895Z"]